BTN3A is a prognosis marker and a promising target for Vγ9Vδ2 T cells based-immunotherapy in pancreatic ductal adenocarcinoma (PDAC)

Giuseppe Montalto, Céline Loncle, Audrey Benyamine, Véronique Secq, Anne-Sophie Chrétien, Céline Castanier, Etienne Foucher, Elena Vila-Navarro, Juan-Luis Blazquez, Mauro Modesti, Etienne Foucher, Meritxell Gironella, Nelson Dusetti, Jean-Charles Dagorn, Salem Chouaib, Juan Iovanna, Daniel Olive

Research output: Contribution to journalArticlepeer-review

16 Citations (Scopus)

Abstract

Vγ9Vδ2 T cells are anti-tumor immune effectors of growing interest in cancer including Pancreatic Ductal Adenocarcinoma (PDAC), an especially aggressive cancer characterized by a hypoxic and nutrient-starved immunosuppressive microenvironment. Since Butyrophilin 3 A (BTN3A) isoforms are critical activating molecules of Vγ9Vδ2 T cells, we set out to study BTN3A expression under both basal and stress conditions in PDAC primary tumors, and in novel patient-derived xenograft and PDAC-derived cell lines. BTN3A2 was shown to be the most abundant isoform in PDAC and was stress-regulated. Vγ9Vδ2 T cells cytolytic functions against PDAC required BTN3A and this activity was strongly enhanced by the agonist anti-BTN3A 20.1 mAb even under conditions of hypoxia. In PDAC primary tumors, we established that BTN3A expression and high plasma levels of soluble BTN3A were strongly associated with a decreased survival. These findings may have important implications in the design of new immunotherapeutic strategies that target BTN3A for treating PDAC.
Original languageEnglish
Pages (from-to)e1372080-
Number of pages14
JournalOncoImmunology
Volume7
Publication statusPublished - 2017

All Science Journal Classification (ASJC) codes

  • Immunology and Allergy
  • Immunology
  • Oncology

Fingerprint Dive into the research topics of 'BTN3A is a prognosis marker and a promising target for Vγ9Vδ2 T cells based-immunotherapy in pancreatic ductal adenocarcinoma (PDAC)'. Together they form a unique fingerprint.

Cite this